The DHEA ELISA Assay Kit (enzyme-linked immunoassay kit) is intended for the quantitative determination of Dehydroepiandrosterone (DHEA) in human serum by an enzyme immunoassay. The Dehydroepiandrosterone (DHEA) ELISA Assay Kit is for research use only and not to be used in diagnostic procedures.

SKU: DHA31-K01 Categories: , ,


The DHEA ELISA Assay Kit is for research use only

Size: 1×96 wells
Sensitivity: 0.15 ng/mL
Dynamic Range: 0.2–40 ng/mL
Incubation Time: 75 minutes
Sample Type: Serum
Sample Size: 25 µL
Controls Included

Assay Principle

The principle of the following enzyme immunoassay test follows the typical competitive binding scenario. Competition occurs between an unlabelled antigen (present in standards, controls and patient samples) and an enzyme-labelled antigen (conjugate) for a limited number of antibody binding sites on the microplate. The washing and decanting procedures remove unbound materials. After the washing step, the enzyme substrate is added. The enzymatic reaction is terminated by addition of the stopping solution. The absorbance is measured on a microtiter plate reader. The intensity of the colour formed is inversely proportional to the concentration of DHEA in the sample. A set of standards is used to plot a standard curve from which the amount of DHEA in patient samples and controls can be directly read.

Typical Standard Curve

Related Products for DHEA ELISA


Additional Information

Assay Background

DHEA Dehyroepiandrosterone is a C19 steroid produced in the adrenal cortex and to a lesser extent in the gonads. DHEA serves as precursor in testosterone and estrogen synthesis. Due to the presence of a 17-oxo-group, DHEA has relatively weak androgenic activity, which has been estimated at ~10% that of testosterone. However, in neonates, peripubertal children and in adult women, circulating DHEA levels may be several fold higher than testosterone concentrations, and rapid peripheral tissue conversion to more potent androgen (androstenedione and testosterone) and estrogen may occur. Moreover, DHEA has relatively low affinity for sex-hormone binding globulin. These factors may enhance the physiologic biopotency of DHEA. The physiologic role of DHEA has not been conclusively defined. A variety of in vivo and in vitro effects have been demonstrated, including antitumoral effects by provoking prevention and/ or regression in spontaneous or chemically induced skin and colon cancers in rodents. A few reports have suggested low production of DHEA(S) in women at risk of or having breast cancer. Therapeutic activity of DHEA has been reported for animals with diabetes of genetic origin, obesity and cardiovascular disease. There are also effects of DHEA in immune function, lipid metabolism, cholesterol, the nervous system, aging and in protection against virus development. Serum DHEA levels are relatively high in the fetus and neonates, low during childhood, and increase during puberty until the third decade of life. No consistent change in serum DHEA levels occur during the menstrual cycle or pregnancy. DHEA has a rapid metabolic clearance rate as compared to its sulfated conjugate, DHEA-S. Because of this, serum DHEA levels are 100–1000 fold lower than DHEA-S levels. In addition serum DHEA levels show significant diurnal variation which is dependent on adrenocorticotropic hormone (ACTH). Measurement of serum DHEA is a useful marker of adrenal androgen synthesis. Abnormally low levels may occur in hypoadrenalism, and elevated levels may occur in several conditions including virilizing adrenal adenoma and carcinoma, 21-hydroxylase and 3b-hydroxysteroid dehydrogenase deficiencies and in some case of female hirsutism.

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations